Pheochromocytoma: Why a Clear Family History Isn’t Reassuring

Pheochromocytoma is a catecholamine-producing tumor arising from chromaffin cells of the adrenal medulla; its extra-adrenal counterpart is the paraganglioma (PGL). Together, pheochromocytoma and paraganglioma (PCC/PGL) are uncommon, occurring in roughly 2–8 individuals per million each year. What has shifted most in the past two decades is not epidemiology but our understanding of heritability.

The old “10% rule”—that only about 10% of cases are hereditary—no longer holds. Current data show germline pathogenic variants in roughly a third of patients, making pheochromocytoma one of the most heritable of all solid tumors.

---

Frequently asked questions

Should every pheochromocytoma patient have genetic testing?

Clinical guidelines recommend it. Pheochromocytoma/paraganglioma has a strong enough genetic basis — a germline pathogenic variant is identified in up to 30–40% of patients — that guidelines recommend clinical genetic testing for all patients, even those without a family history or syndromic features.

Which genes are most commonly involved?

More than 30 susceptibility genes are known. The succinate dehydrogenase complex (SDHB, SDHD, SDHC, SDHA, SDHAF2), VHL, RET, NF1, and MAX account for most hereditary cases.

Why does an SDHB mutation matter clinically?

Germline SDHB variants carry the highest risk of metastatic disease among the common genes. Identifying an SDHB carrier prompts closer, lifelong biochemical and imaging surveillance and cascade testing of relatives.

Is a negative family history reassuring?

No. Sporadic-appearing tumors still carry an 11–13% chance of a germline mutation, and imprinting effects can mask inheritance. Family history alone should never determine whether testing is offered.

---

Why the genetics changed the standard of care

For decades, hereditary pheochromocytoma was assumed to be the exception. Systematic germline testing overturned that view. In one cohort of 101 sporadic-appearing PCC/PGL cases, 36.6% harbored germline mutations, with SDHB the single most frequently mutated gene.

Approximately 40% of all cases are attributable to mutations in one of more than 30 causative genes, and about 25–30% arise within a defined hereditary tumor syndrome. The practical consequence is clear: family history is an unreliable filter, and universal testing captures carriers who would otherwise be missed.

Mechanisms: three molecular pathways

Susceptibility genes cluster into functionally coherent groups, each pointing to a different tumor biology.

Cluster 1 — pseudohypoxia

This group includes the succinate dehydrogenase subunits (SDHA, SDHB, SDHC, SDHD, SDHAF2), VHL, FH, and EPAS1. Loss of SDH complex function disrupts the tricarboxylic acid cycle, causing succinate accumulation that stabilizes hypoxia-inducible factors and drives a pseudohypoxic, pro-angiogenic transcriptional program. VHL variants act through the same HIF axis and, together with SDHx variants, are among the most common cluster 1 (pseudohypoxic) causes of syndromic disease.

Cluster 2 — kinase signaling

Variants in RET (multiple endocrine neoplasia type 2), NF1 (neurofibromatosis type 1), MAX, and TMEM127 activate RAS-RAF-ERK and PI3K-AKT-mTOR signaling. These tumors typically show an adrenergic biochemical phenotype and are more often adrenal and benign than cluster 1 tumors.

Cluster 3 — Wnt signaling

A smaller group driven by somatic CSDE1 mutations and MAML3 fusions defines an aggressive, Wnt-activated subtype. Recognizing cluster membership helps anticipate secretory profile, metastatic potential, and surveillance intensity.

SDHx genes and metastatic risk

Among the hereditary genes, the SDH complex carries the greatest clinical weight. Roughly 15% of PCC/PGL are associated with germline SDH mutations. SDHD variants are highly penetrant and display maternal genomic imprinting—disease typically manifests only when inherited paternally—and account for 40–50% of head and neck paragangliomas.

SDHB deserves particular vigilance. Among malignant PCC/PGL, SDH germline mutations occur at a frequency near 42%, with a marked predominance of SDHB. Because 15–25% of PCC/PGL metastasize and metastatic disease carries only a 43–69% five-year survival, identifying an SDHB carrier directly informs prognosis and the tempo of follow-up.

Who to test, and what a diagnosis changes

The case for universal germline testing rests on penetrance and prognostic value. A sporadic-appearing tumor still carries an 11–13% likelihood of an underlying germline mutation—reason enough to test regardless of family history. In children, the hereditary fraction is even higher: about 60% of pediatric cases are associated with a germline mutation.

A confirmed molecular diagnosis reshapes care in several concrete ways:

• Surveillance: gene-specific protocols dictate the frequency and modality of biochemical testing and whole-body imaging.
• Metastatic risk stratification: SDHB status flags patients needing more intensive monitoring.
• Multi-tumor screening: VHL, RET, and NF1 carriers require organ-specific screening beyond the adrenal.
• Cascade testing: at-risk relatives can be identified presymptomatically, with imprinting considered for SDHD and SDHAF2.

Given more than 30 implicated genes, a multi-gene panel or exome-based approach is more efficient than sequential single-gene testing.

* This article is educational and does not replace individualized medical advice. Diagnostic and management decisions should be made with a qualified clinician.

---

References

1. Raygada M, Pasini B, Stratakis CA. Hereditary paragangliomas. 2011. https://doi.org/10.1159/000322484
2. Choat H, Derrevere K, Knight L, Brown W, Mack EH. SDHB-Associated Paraganglioma in a Pediatric Patient and Literature Review on Hereditary Pheochromocytoma-Paraganglioma Syndromes. 2014. https://doi.org/10.1155/2014/502734
3. Zhikrivetskaya SO, Snezhkina AV, Zaretsky AR, et al. Molecular markers of paragangliomas/pheochromocytomas. 2017. https://doi.org/10.18632/oncotarget.15201
4. Kavinga Gunawardane PT, Grossman A. The clinical genetics of phaeochromocytoma and paraganglioma. 2017. https://doi.org/10.1590/2359-3997000000299
5. Albattal S, Alswailem M, Moria Y, et al. Mutational profile and genotype/phenotype correlation of non-familial pheochromocytoma and paraganglioma. 2019. https://doi.org/10.18632/oncotarget.27194
6. Turin CG, Crenshaw MM, Fishbein L. Pheochromocytoma and paraganglioma: germline genetics and hereditary syndromes. 2022. https://doi.org/10.1530/EO-22-0044
7. Mauer Hall CB, Watson EM, Prasad T, Myers CL, Mersch JA. Hereditary and clinical insights into paraganglioma and pheochromocytoma. 2024. https://doi.org/10.1530/EO-24-0029